Clinical Trials Directory

Trials / Unknown

UnknownNCT02166515

The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Zhiqing, Liang · Academic / Other
Sex
Female
Age
16 Years – 75 Years
Healthy volunteers
Accepted

Summary

As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies. In recent years, the incidence of cervical cancer, especially in young women significantly increased; ovarian cancer, although the incidence of malignant tumors in the female reproductive system ranked second, but its mortality rate already in the first place; and the morbidity and mortality of endometrial cancer is also rising. The key to gynecologic malignancies is how to early diagnose and treat. With the advancement of science and technology, such as molecular biology techniques widely used in the medical field, early diagnosis, proper treatment and other aspects in gynecologic malignancies is expected to achieve a breakthrough. Genome-wide scan strategy, making the whole genome for linkage analysis for gynecological malignancies possible. Therefore, the investigators intend to find specific mutations to provide a new early screening approach for gynecological malignancies, which in later result in early diagnosis and specific treatment for gynecological malignant tumors.

Conditions

Timeline

Start date
2013-10-01
Primary completion
2016-10-01
Completion
2017-10-01
First posted
2014-06-18
Last updated
2014-06-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02166515. Inclusion in this directory is not an endorsement.

The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor (NCT02166515) · Clinical Trials Directory